Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Keywords

Medicine, Docetaxel, Pemetrexed, Neutropenia, Internal medicine

References

• Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?Roberto Grilli, Andrew D Oxman, Jim A. Julian — 1993
• Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard DeviationGeoffrey R. Norman, Jeff A. Sloan, Kathleen W. Wyrwich — 2003
• Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaStephanie Green, Geoffrey R. Weiss — 1992
• Current Data with Pemetrexed in Non-Small-Cell Lung CancerAlex A. Adjei — 2003
• A COMPARISON OF APPROXIMATE INTERVAL ESTIMATORS FOR THE BERNOULLI PARAMETERLawrence M. Leemis, Kishor S. Trivedi — 1993
• Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scalePatricia J. Hollen, Richard J. Gralla, Mark G. Kris — 1994
• Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski — 2003
• ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study.Egbert F. Smit, K. Mattson, Joachim von Pawel — 2003
• Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.Frances A. Shepherd, Janet Dancey, Rodryg Ramlau — 2000
• Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.James J. Rusthoven, Elizabeth A. Eisenhauer, Charles Butts — 1999
• Design and analysis of non‐inferiority mortality trials in oncologyMark D. Rothmann, Ning Li, Gang Chen — 2002
• Statistical aspects of the analysis of data from retrospective studies of disease.Nathan Mantel, William Haenszel — 1959
• Current data with pemetrexed (Alimta) in non-small-cell lung cancer.Alex A. Adjei — 2003
• The big lung trial (BLT): Determining the value of cisplatin- based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care settingRJ Stephens, Julia Brown, DJ Fairlamb — 2002
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsNon-small Cell Lung Cancer Collaborative Group — 1995
• Corrigendum to “Cancer burden in the year 2000. The global picture” [European Journal of Cancer,37(Suppl. 8) (2001) S4–S66]D. Parkin, F. Bray, S. Devesa — 2003

Cited by

• Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer.J. J. Wolford — 2005
• The economic burden of lung cancer and the associated costs of treatment failure in the United States.Tomás Lomo Casanueva — 2005
• 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.Fernando Castro Flórez — 2006
• Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter匡梅, 王素娟, 李瑶 — 2007
• Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumabThomas E. Stinchcombe — 2007
• Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients.Jennifer S. Temel, Vicki A. Jackson, J. Andrew Billings — 2007
• Survival improvement in thoracic cancer: progress from the last decade and beyond.Ascensión Carretero Jumilla — 2007
• Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer.Rafael Lemus — 2008
• Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug DevelopmentY Wang, Chong Won Sung, Céline Dartois — 2009
• Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Zielinski — 2009
• The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.Носачевская Екатерина Александровна — 2010
• Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer浩文 左右田 — 2010
• Biweekly Vinorelbine and Gemcitabine as Second-Line Treatment and Beyond in Non-Small Cell Lung CancerSéverine Ménager-Sibé — 2010
• Pemetrexed in the treatment of thoracic malignancies: a single centre experience in Singapore.Gilberto Lopes, Akhil Chopra, J. Kukutschka — 2011
• A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.Lawrence J. Shadle, C.J. Ludlow, James Spenik — 2012
• Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness AnalysisAb. Latif, Abdul Aziz — 2011
• ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung CancerKrzysztof Bielecki, Iwona Trytko — 2012
• Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors貞介 児玉, 太郎 山中, 重道 菅原 — 2013
• Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.Jesús Marino Pascual Vicente — 2013
• Pemetrexed-Carboplatin Adjuvant Chemotherapy With or Without Gefitinib in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Harbouring EGFR Mutations: A Randomized, Phase II StudyMauro Mazza — 2014

Related papers

• Clinical observation of the effects of pemetrexed or docetaxel as second-line drug for advanced non-small cell lung cancer in elderly patientsPU Xiao-li — 2010
• Clinical observation on effects of single second-line drug pemetrexed or docetaxel for treating elderly advanced non-small cell lung cancerLI Hua-nian — 2011
• Clinical observation of pemetrexed or docetaxel plus cisplatin in the treatment of patients with advanced non-small cell lung cancerXu Ling — 2013
• Pemetrexed monotherapy in patients with advanced non-small cell lung cancer who have had prior chemotherapy: A prospective phase II trialH. Lee, M.-J. Ahn, Jong‐Hwa Ahn — 2008
• Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to ageDae Young Zang, Dae Hyun Yang, Hae Wan Lee — 2009
• Docetaxel and cisplatin in patients with advanced gastric cancer: results of Japanese phase I/II studySoh Saitoh, Yuh Sakata — 2002
• Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408Koichi Takayama, Junji Uchino, Masaki Fujita — 2019
• A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).Ornella Belvedere, Alessandro Follador, C. Rossetto — 2011
• Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung CancerMihong Choi, Heung Tae Kim, Ji‐Youn Han — 2020
• Efficacy and safety of modified ECF regimen as first-line chemotherapy in metastatic gastric adenocarcinoma: A phase II study.Tamojit Chaudhuri, Govind Babu, KC Lakshmaiah — 2018